

## Winston Pharmaceuticals, Inc. to Present at Lazard Capital Markets 7<sup>th</sup> Annual Healthcare Conference

**Vernon Hills, Illinois – November 10, 2010** - Winston Pharmaceuticals, Inc. (“Winston”), a pharmaceutical company focused on developing and commercializing novel pain management therapies today announced that senior management will present at the Lazard Capital Markets 7<sup>th</sup> Annual Healthcare Conference on Wednesday, November 17, 2010 at 3:45PM EST. The conference will be held at the St. Regis in New York City. Winston senior management will provide a review of recent corporate developments.

The Company's presentation slides will be available on the Winston's website on the day of the presentation. To access the slides go to the Winston Pharmaceuticals, Inc. website at [www.winstonlabs.com](http://www.winstonlabs.com) and click on the icon for Investor Relations home page.

### **About Winston Pharmaceuticals**

Winston is a pharmaceutical company focused on pain control which is developing products for large pain control markets, as well as for niche markets, where there are still significant unmet needs for pain management options with improved efficacy, safety, and tolerability profiles. Winston's late stage candidates include episodic cluster headache, chronic migraine headache, osteo-and rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease.

*This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking statements also may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.*

CONTACT: Winston Pharmaceuticals, Inc.

David Starr, Chief Financial Officer

(847) 362-8200